
Craif Inc. is a pioneering biotechnology company focused on early, painless, and highly accurate cancer detection through urine-based liquid biopsy using exosome extraction technology. Their flagship product, MySignal®, developed in collaboration with about 30 university hospitals and cancer research centers, enables high-precision cancer risk testing from urine and saliva samples. Craif's proprietary NANO IP® platform captures, measures, analyzes, and databases nanobiomarkers to optimize treatment for various diseases. The company aims to create a society where people can live healthy lives to their natural lifespan by enabling early disease detection and treatment optimization. Craif operates a B2B model supporting corporate health management to reduce cancer-related workforce attrition and has research and laboratory facilities in Japan and the US. Their leadership team includes experienced founders and scientific advisors with strong backgrounds in oncology, nanotechnology, and machine learning. Investors include ANRI, Daiwa Corporate Investment, Aflac Ventures, and others, reflecting strong market confidence.

Craif Inc. is a pioneering biotechnology company focused on early, painless, and highly accurate cancer detection through urine-based liquid biopsy using exosome extraction technology. Their flagship product, MySignal®, developed in collaboration with about 30 university hospitals and cancer research centers, enables high-precision cancer risk testing from urine and saliva samples. Craif's proprietary NANO IP® platform captures, measures, analyzes, and databases nanobiomarkers to optimize treatment for various diseases. The company aims to create a society where people can live healthy lives to their natural lifespan by enabling early disease detection and treatment optimization. Craif operates a B2B model supporting corporate health management to reduce cancer-related workforce attrition and has research and laboratory facilities in Japan and the US. Their leadership team includes experienced founders and scientific advisors with strong backgrounds in oncology, nanotechnology, and machine learning. Investors include ANRI, Daiwa Corporate Investment, Aflac Ventures, and others, reflecting strong market confidence.
Company Description
Craif is a rapidly growing Japanese biotech startup with a commercially successful diagnostics business, generating over $1,400,000 in monthly revenue through partnerships with more than 2000 medical institutions in Japan. Leveraging our cutting-edge urine-based miRNA assay platform for early cancer detection, we are now expanding our operations to the United States.
We are seeking a dedicated and innovative Staff Scientist who is passionate about building both technologies and laboratory infrastructure from the ground up as we establish a new U.S. based research facility.
Position Summary
The Staff Scientist will play a key role in developing, optimizing, and validating miRNA-based assays using liquid samples, with a strong focus on urine. This role involves executing complex wet-lab experiments, establishing laboratory capabilities, and collaborating closely with scientific teams in both the U.S. and Japan. This is a full-time, onsite position located in San Diego, CA.
Key Responsibilities
Minimum Qualifications
8+ years of relevant industry experience with a Bachelor’s degree
5+ years of relevant industry experience with a Master’s degree
2+ years of relevant industry experience with a PhD.
Preferred Qualifications
Working Style
We are looking for a scientist who is:
Salary Range
The estimated base salary range for this position is $125,000 – $160,000 (USD).